Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 7/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7102603 | 1.00 | ITGB3 (0.52) | ITGB3ITGA2BPTPN1ACEITGA4 | |
| SCHEMBL5259419 | 0.92 | ITGB3 (0.43) | ITGB3ITGA2BPTPN1ITGA4ITGB7 | |
| SCHEMBL5259415 | 0.92 | ITGB3 (0.43) | ITGB3ITGA2BPTPN1ITGA4ITGB7 | |
| SCHEMBL31407761 | 0.84 | ITGB3 (0.61) | ITGB3ITGA2BPTPN1ACEITGA4 | |
| SCHEMBL6537537 | 0.84 | ITGB3 (0.48) | ITGB3ITGA2BPTPN1ACEITGA4 | |
| SCHEMBL2986557 | 0.84 | ITGB3 (0.48) | ITGB3ITGA2BPTPN1ACEITGA4 | |
| SCHEMBL2978498 | 0.83 | ITGB3 (0.48) | ITGB3ITGA2BPTPN1ACEITGA4 | |
| SCHEMBL7104303 | 0.83 | ITGB3 (0.48) | ITGB3ITGA2BPTPN1ACEITGA4 | |
| SCHEMBL5182529 | 0.82 | LATS1 (0.40) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL5182540 | 0.82 | P2RX7 (0.37) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | ITGB3 10/4885ITGA2B 55/4885PTPN1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.